Inspire Medical Systems Achieves Major Milestones in Q3
Inspire Medical Systems Inc (NYSE: INSP) recently released its third-quarter financial results, surprising analysts with strong earnings and significantly raised guidance for the upcoming fiscal year.
Outstanding Quarterly Earnings Report
The company reported earnings of 38 cents per share, surpassing the consensus estimate which anticipated a loss of 19 cents. Additionally, total sales reached $224.501 million, edging out forecasts that predicted $220.467 million.
Revised Guidance for FY2025
Following these remarkable results, Inspire Medical Systems adjusted its fiscal year 2025 guidance. The GAAP EPS expectation was increased from a range of $0.40-$0.50 to $0.90-$1.00, while sales guidance remained firm at $900.000 to $910.000 million.
Leadership Insight
CEO Tim Herbert expressed optimism regarding the quarter, stating, "The Inspire team had a very productive third quarter focusing on the transition to the Inspire V system while delivering very strong results globally. Further, at recent industry meetings, we showcased clinical evidence demonstrating that the Inspire V system offers enhanced performance, building on the foundations established by our legacy systems."
Stock Response to Earnings
In light of this financial performance, Inspire Medical shares surged by 17%, bringing the trading price to $86.46.
Analyst Ratings Adjustments Post-Earnings
In response to the earnings announcement from Inspire Medical, several analysts adjusted their evaluations and price targets:
- Wells Fargo's Larry Biegelsen upgraded the stock from Equal-Weight to Overweight while reducing the price target from $101 to $90.
- JP Morgan’s Robbie Marcus maintained a Neutral rating but lowered the target from $110 to $82.
- Richard Newitter of Truist Securities reiterated a Hold rating and decreased the price target from $90 to $84.
- Shagun Singh from RBC Capital kept an Outperform rating, lowering the target from $150 to $125.
- Piper Sandler’s Adam Maeder reiterated an Overweight rating, cutting the price target from $150 to $135.
Analyst Insights on Investment Potential
For those considering investments in INSP stock, analysts have provided various perspectives worth considering based on the latest earnings and guidance increases.
Frequently Asked Questions
What were Inspire Medical's earnings for Q3?
Inspire Medical reported earnings of 38 cents per share, exceeding expectations.
How much did sales reach in Q3?
The total sales for Q3 reached $224.501 million.
What guidance did Inspire Medical raise?
The company raised its FY2025 GAAP EPS guidance from $0.40-$0.50 to $0.90-$1.00.
What is the stock response to the earnings report?
Inspire Medical stock increased by 17% following the earnings report.
What are the updated price targets from analysts?
Analysts have adjusted price targets, with figures varying from $82 to $135 based on their evaluations.
